Midwest Trust Co Makes New $7.99 Million Investment in Becton, Dickinson and Company $BDX

Midwest Trust Co bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 46,378 shares of the medical instruments supplier’s stock, valued at approximately $7,989,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the first quarter worth $26,000. Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $31,000. Bank of Jackson Hole Trust boosted its position in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the last quarter. WPG Advisers LLC purchased a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $36,000. Finally, CVA Family Office LLC increased its position in Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 97 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BDX. Royal Bank Of Canada decreased their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a report on Friday. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $203.27.

Becton, Dickinson and Company Trading Up 0.3%

Shares of NYSE BDX opened at $177.88 on Monday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $186.77 and a 200-day simple moving average of $182.15. The stock has a market capitalization of $50.99 billion, a PE ratio of 31.99, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion for the quarter. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 71.36%.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,249 shares of company stock valued at $231,358. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.